<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584632</url>
  </required_header>
  <id_info>
    <org_study_id>CL05122020</org_study_id>
    <nct_id>NCT04584632</nct_id>
  </id_info>
  <brief_title>The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery</brief_title>
  <acronym>Efemoral I</acronym>
  <official_title>A Clinical Evaluation of the Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Efemoral Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Efemoral Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the EVSS in patients with symptomatic peripheral&#xD;
      vascular disease from stenosis or occlusion of the femoropopliteal artery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EFEMORAL I study is a prospective, single-arm, open-labeled, multi-center, clinical&#xD;
      investigation enrolling patients with arterial diameter of ≥5.5 mm and ≤6.5 mm and lesion&#xD;
      length ≤90 mm receiving a single EVSS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Event (MAE)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Binary Restenosis</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 0</time_frame>
    <description>Achievement of successful delivery and deployment of the study device(s) at the intended target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral extremity revascularization (IER)</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Scaffold thrombosis</measure>
    <time_frame>through 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with scaffold occlusion</measure>
    <time_frame>6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Limb Events</measure>
    <time_frame>through 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial index (ABI) of target extremity</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb salvage of target extremity</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford-Becker Clinical Category for the target extremity</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking impairment as assessed by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Up to 2 days after procedure</time_frame>
    <description>Attainment of a final residual stenosis of &lt;30% using the study device(s) and/or any adjunctive device at the intended target lesion without complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Day 0</time_frame>
    <description>Attainment of a final residual stenosis of &lt;30% at the intended target lesion(</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Target lesion percent mean diameter stenosis</measure>
    <time_frame>Post procedure (Day 0) and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Target lesion percent maximum diameter stenosis</measure>
    <time_frame>post procedure (day 0) and at 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Target lesion late lumen loss</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ischemia-driven target lesion revascularization (IDTLR)</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Amputation (minor and major) of the target extremity</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Vascular Diseases</condition>
  <condition>Stenosis</condition>
  <condition>Femoropopliteal Stenosis</condition>
  <arm_group>
    <arm_group_label>EVSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efemoral Vascular Scaffold System (EVSS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Efemoral Vascular Scaffold System (EVSS)</intervention_name>
    <description>Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus</description>
    <arm_group_label>EVSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic peripheral vascular occlusive disease (Rutherford-Becker Clinical Category&#xD;
             2-4)&#xD;
&#xD;
          -  Patient with life expectancy &gt;36 months&#xD;
&#xD;
          -  Females of childbearing potential must have negative pregnancy test&#xD;
&#xD;
          -  Patient is able to provide informed consent&#xD;
&#xD;
          -  Patient agrees to undergo all protocol-required follow-up examinations and&#xD;
             requirements at the investigational site.&#xD;
&#xD;
          -  Patient must be able to take antiplatelet and/or anticoagulant agents as prescribed&#xD;
&#xD;
          -  Single de novo native disease segment of the superficial femoral artery (SFA) or P1&#xD;
             popliteal segment&#xD;
&#xD;
          -  Reference vessel diameter ≥5.5 mm and ≤6.5 mm&#xD;
&#xD;
          -  Target lesion length ≤90 mm&#xD;
&#xD;
          -  Target lesion with ≥50% DS&#xD;
&#xD;
          -  Inflow artery and popliteal artery free from flow-limiting lesion (DS &lt;50%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin &lt;9.0 g/dL&#xD;
&#xD;
          -  WBC &lt;3,000 cells/mm3&#xD;
&#xD;
          -  Platelet count &lt;80,000 cells/mm3 or &gt;700,000 cells/mm3&#xD;
&#xD;
          -  Acute or chronic renal dysfunction with creatinine &gt;2.5 mg/dl (176 µmol/L)&#xD;
&#xD;
          -  Severe liver impairment as defined by total bilirubin ≥3 mg/dl or two times increase&#xD;
             over the normal level of SGOT or SGPT&#xD;
&#xD;
          -  A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin,&#xD;
             ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be&#xD;
             adequately pre-medicated&#xD;
&#xD;
          -  Patient requires a planned procedure that would necessitate discontinuation of&#xD;
             antiplatelet therapy&#xD;
&#xD;
          -  Patient is unable to walk&#xD;
&#xD;
          -  Patient has undergone a percutaneous vascular intervention &lt;30 days prior to the&#xD;
             planned index procedure&#xD;
&#xD;
          -  Patient is maintained on chronic hemodialysis&#xD;
&#xD;
          -  Patient has uncontrolled diabetes mellitus (HbA1c ≥7.0%).&#xD;
&#xD;
          -  Patient has had a myocardial infarction within the previous 30 days of the planned&#xD;
             index procedure&#xD;
&#xD;
          -  Patient has had a stroke within the previous 30 days of the planned index procedure&#xD;
             and/or has deficits from a prior stroke that limits the patient's ability to walk&#xD;
&#xD;
          -  Patient has unstable angina defined as rest angina with ECG changes&#xD;
&#xD;
          -  Patient has a local groin or acute systemic infection that has not been treated&#xD;
             successfully or is currently under treatment&#xD;
&#xD;
          -  Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous&#xD;
             insufficiency in either extremity&#xD;
&#xD;
          -  Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.)&#xD;
             that may cause the patient to be non-compliant with protocol requirements, confound&#xD;
             the data interpretation or will prevent completion of all required follow up&#xD;
             assessments through 36 months&#xD;
&#xD;
          -  Patient is currently participating in an investigational drug, biologic, or device&#xD;
             study that has not completed the primary endpoint or that clinically interferes with&#xD;
             the current study endpoints&#xD;
&#xD;
          -  Patient has ischemic or neuropathic ulcers on either foot&#xD;
&#xD;
          -  Patient has undergone minor or major amputation of either lower extremity&#xD;
&#xD;
          -  Patient is part of a vulnerable population who, in the judgment of the Investigator,&#xD;
             is unable to give informed consent&#xD;
&#xD;
          -  Target extremity with an angiographically significant (&gt;50% DS) lesion located distal&#xD;
             to the target lesion that requires treatment at the time of the index procedure or by&#xD;
             a staged procedure&#xD;
&#xD;
          -  Acute arterial ischemia of the target extremity&#xD;
&#xD;
          -  Target extremity has been previously treated with open surgical revascularization&#xD;
             (bypass or endarterectomy)&#xD;
&#xD;
          -  Target vessel has been previously treated with stent, laser, atherectomy, surgical&#xD;
             bypass, or endarterectomy&#xD;
&#xD;
          -  Total occlusion (100% DS) of the ipsilateral inflow artery&#xD;
&#xD;
          -  Angiographic evidence of thrombus in the target vessel&#xD;
&#xD;
          -  The target lesion requires treatment with a device other than percutaneous&#xD;
             transluminal balloon angioplasty (PTA) [e.g., orbital atherectomy, directional&#xD;
             atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.]&#xD;
&#xD;
          -  Target lesion is within or adjacent to an aneurysm&#xD;
&#xD;
          -  Patient has angiographic evidence of thromboembolism or atheroembolism from treatment&#xD;
             of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion&#xD;
&#xD;
          -  Target lesion has moderate-to-severe calcification&#xD;
&#xD;
          -  Target lesion with &gt; 30% residual stenosis following pre-dilatation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lew Schwartz, MD</last_name>
    <phone>224-707-2601</phone>
    <email>lewis.schwartz@efemoralmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Holden, MD</last_name>
      <phone>6493670000</phone>
      <email>andrewh@adhb.govt.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Bioresorbable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

